Safety, pharmacokinetics, and preliminary efficacy of VIR-5500 (AMX-500) in prostate cancer

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-503495-24-00

Acronym

VIR-5500-V101

Enrollment

Registered

2023-09-26

Start date

2023-10-30

Completion date

Unknown

Last updated

2025-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hormone-refractory prostate cancer

None listed

Sex/Gender

Male

Age

18 Years to No maximum

Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026